Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2020.01.06
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following ...
PDF (253 KB)
2020.01.27
Phase 2 DESTINY-Gastric01 Trial of DS-8201 Versus Chemotherapy Met Primary Endpoint
PDF (156 KB)
2020.03.25
ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic ...
PDF (236 KB)
2020.03.30
Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patie ...
PDF (149 KB)
2020.05.07
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Tr ...
PDF (174 KB)
2020.05.11
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric ...
PDF (179 KB)
2020.05.13
Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting
PDF (230 KB)
2020.05.15
Daiichi Sankyo to Present New Preclinical and Translational Research from DXd ADC Portfolio at AACR ...
PDF (198 KB)
2020.05.18
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small ...
PDF (179 KB)
2020.05.21
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
PDF (186 KB)
Showing 1 - 10 of 37 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...